Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com
Research analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a note issued to investors on Friday. The firm set a “sell” rating on the stock. Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Moleculin Biotech in a research report […]
More Stories
What a New Roof Really Costs in Texas: A 2026 Budget Guide
The roof is the most expensive part of a house that most owners never look at. One spring storm can...
Haunted Hotel Season 3: Netflix Release Date, Cast, Plot, and More
If you are a fan of anime movies and series, this blog is for you! Popular 2025 American adult animated...
Massive Alaska North Slope Gas Discovery Could Power US for Nearly 3 Years
By Naveen Athrappully Alaska’s North Slope region could contain 96 trillion cubic feet of undiscovered and technically recoverable natural gas...
UK Must Be Ready for War in 1,000 Days, Says British Defense Secretary
By Rachel Roberts British Defense Secretary Wes Streeting has said the country must be ready for war in 1,000 days,...
Trump Offers $1 Million to Anyone Who Reports Voter Fraud Leading to Conviction
By Jack Phillips President Donald Trump on Monday said that he would provide $1 million to people who can report...
Federal Judge Strikes Down New York Body Armor Ban
By Jack Phillips A federal judge this past week overturned New York state’s ban on the sale and purchase of...